Logo

Sengenics to Sell Sequenom's MaterniT21 Test in Malaysia, Singapore

Nov 12, 2012 | staff reporter

NEW YORK (GenomeWeb News) – Sengenics today said that it has entered into an exclusive agreement with the Sequenom Center for Molecular Medicine to launch and promote Sequenom's MaterniT21 Plus prenatal testing service in Malaysia and Singapore.

Sengenics will offer the test, which detects Trisomy 13, 18, and 21, to its partner Ob/Gyn clinicians and hospitals in the two countries. Sengenics is based in Kuala Lumpur and offers genomic-based diagnostic services. It added that it has contracts with eight of the top 10 private hospital chains in the region.

Sequenom on Friday said that it has reached a 90,000 annualized test volume run rate for MaterniT21, approximately one year after the test was launched in the US.

Filed under

Clinical Sequencing
Sequencing
Diagnostics
Business News
Disease Research
services alliance
marketing agreement
aneuploidy
sequencing-based diagnostics
Laboratory Corporation of America
Sengenics
Breaking News
The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.